This information was published on 2022-08-08T00:25:44 for IP Right Acceptance Published.
| Field | Value |
| (210) | 2258485 (IR 1640410) |
| (220) |
07 Mar 2022
|
| (511) (510) |
Class 5
Pharmaceuticals, namely, aldosterone synthase inhibitors for treatment of primary aldosteronism, hypertension, kidney disease, liver disease, heart failure. |
| (540) | CINCOR |
| (550) | Word |
| (730) |
Cincor Pharma, Inc.
|
Find out more about publications on the About page.